In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Creative BioMolecules, Ontogeny, Reprogenesis merge

Executive Summary

Creative BioMolecules (tissue regeneration) will acquire private developmental biology biotech Ontogeny and tissue-engineering company Reprogenesis to form a new company Curis--with cash reserves of $70mm--in which CBM will have a 43% position, Ontogeny a 38% stake, and Reprogenesis will hold 19%. For every three Curis shares, stockholders will receive ten CBM shares.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
    • Drug Discovery Tools
      • Genomics-Proteomics
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Contract
    • Payment Includes Stock

Related Companies